CDK4 and breast cancer: The progression-free survival (PFS) and, in some cases, overall survival (OS) of patients diagnosed with invasive BC has dramatically improved with the introduction of inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6is).